satavaptan has been researched along with Diabetic Nephropathies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alhenc-Gelas, F; Bankir, L; Bouby, N; Chollet, C; El Boustany, R; Roussel, R; Taveau, C; Velho, G | 1 |
1 other study(ies) available for satavaptan and Diabetic Nephropathies
| Article | Year |
|---|---|
Antagonism of vasopressin V2 receptor improves albuminuria at the early stage of diabetic nephropathy in a mouse model of type 2 diabetes.
Topics: Albuminuria; Animals; Antidiuretic Hormone Receptor Antagonists; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Kidney Glomerulus; Male; Mice; Mice, Inbred C57BL; Morpholines; Receptors, Vasopressin; Spiro Compounds | 2017 |